Novo Nordisk Under Dual Scrutiny: Tax Transparency and Emerging Neurological Findings
Novo Nordisk, the Danish multinational specializing in diabetes and obesity therapeutics, found itself in the spotlight on 30 May 2026 through two disparate reports that together highlight both financial and scientific challenges facing the company. A tax‑governance assessment by ProInvestor positioned the company low in a ranking of life‑science firms for transparency, while a Hindustan Times feature reported preliminary neurological effects associated with the company’s glucagon‑like peptide‑1 (GLP‑1) drugs, notably Ozempic (semaglutide) and Mounjaro (tirzepatide).
1. Tax Transparency Assessment
1.1 ProInvestor’s Evaluation Framework
ProInvestor’s report applied a composite score that measured three key dimensions:
- Disclosure of tax policy – whether the company publishes a comprehensive policy statement outlining its approach to tax planning and compliance.
- Reporting of tax expense and revenue – consistency and granularity of tax expense items in audited financial statements.
- Public commentary on tax matters – engagement with regulatory bodies and the public regarding tax controversies or reforms.
Novo Nordisk received a low score in each of these categories, placing it below peers such as WSA Audiology, Coloplast, and Lundbeck. In contrast, Genmab and LEO Pharma, also Danish life‑science entities, fared similarly poorly, suggesting a broader sectorial trend of limited openness.
1.2 Comparative Landscape
| Company | Disclosure Score (0‑10) | Relative Rank |
|---|---|---|
| Novo Nordisk | 3.1 | 11th |
| Genmab | 3.4 | 10th |
| LEO Pharma | 3.7 | 9th |
| WSA Audiology | 6.8 | 3rd |
| Coloplast | 7.2 | 2nd |
| Lundbeck | 7.5 | 1st |
The discrepancy underscores a sectoral tension: while pharmaceutical companies often have complex, multinational tax structures that justify certain optimizations, the prevailing expectation for transparency is rising, especially in the European Union where regulatory scrutiny is intensifying.
1.3 Regulatory and Investor Implications
European Commission directives, such as the Anti‑Tax Avoidance Directive (ATAD) and forthcoming EU Corporate Sustainability Reporting Directive (CSRD), mandate higher levels of disclosure for corporate sustainability and governance, including tax affairs. Investors increasingly use Environmental, Social, and Governance (ESG) metrics to assess risk; low tax transparency scores may negatively impact Novo Nordisk’s ESG ratings. Consequently, the company may face pressure to publish a dedicated tax policy, provide more granular tax expense disclosures, and engage in stakeholder dialogue to mitigate reputational risk.
2. Neurological Impact of GLP‑1 Therapies
2.1 Pharmacological Basis of GLP‑1 Agonists
GLP‑1 receptors are expressed not only in pancreatic β‑cells and the gastrointestinal tract but also throughout the central nervous system (CNS), notably in the hypothalamus, amygdala, and prefrontal cortex. Activation of these receptors:
- Enhances glucose‑dependent insulin secretion.
- Suppresses glucagon release.
- Modulates appetite via hypothalamic circuits (e.g., AgRP/NPY and POMC neurons).
- Influences reward pathways, potentially affecting addiction and motivation.
Semaglutide and tirzepatide, while primarily designed for glycaemic control, act centrally through their ability to cross a partially permeable blood‑brain barrier and bind to GLP‑1 receptors in the brain, thereby affecting neuronal plasticity and synaptic strength.
2.2 University of Colorado Anschutz Study Overview
The referenced study enrolled 28 young adults (age 18–35) with obesity who received weekly subcutaneous injections of semaglutide or tirzepatide for 12 weeks. Functional magnetic resonance imaging (fMRI) assessed resting‑state connectivity and task‑based activation during cognitive and affective paradigms. Key findings included:
| Outcome | Semaglutide (n=14) | Tirzepatide (n=14) |
|---|---|---|
| Increase in frontoparietal connectivity | +12% (p < 0.05) | +18% (p < 0.01) |
| Reduced activation in amygdala during emotional stimuli | -9% (p < 0.05) | -12% (p < 0.05) |
| Subjective reports of “cognitive fog” | 4/14 (29%) | 6/14 (43%) |
| Decrease in self‑reported motivation | 3/14 (21%) | 5/14 (36%) |
The study is exploratory, limited by sample size and lack of a placebo arm. Nevertheless, the observed changes in neural circuits suggest that GLP‑1 agonists may modulate both executive function and emotional processing.
2.3 Clinical Trial Evidence and Safety Signals
Large‑scale Phase III trials for obesity (e.g., STEP 1–STEP 4 for semaglutide, SURPASS‑4 for tirzepatide) reported weight loss averages of 15–20 % of baseline body weight and improvements in metabolic syndrome markers. Adverse event profiles primarily included gastrointestinal symptoms (nausea, diarrhea). Neurological adverse events were not systematically captured, as trials were not powered for cognitive endpoints. Emerging post‑marketing data from pharmacovigilance databases indicate a low incidence of headache, dizziness, and “brain fog,” but causality remains unestablished.
2.4 Potential Therapeutic Opportunities and Risks
Opportunities:
- Addiction Modulation: Preclinical studies show GLP‑1 receptor activation reduces drug‑seeking behavior in rodent models of cocaine and opioid use disorders.
- Alzheimer’s Disease: GLP‑1 agonists improve insulin sensitivity in the brain, potentially attenuating amyloid‑β deposition and tau hyperphosphorylation. Phase II trials of semaglutide in mild cognitive impairment have demonstrated stabilization of neuropsychological scores.
- Stress Resilience: Modulation of the hypothalamic‑pituitary‑adrenal axis by GLP‑1 may confer anxiolytic effects, as suggested by animal models.
Risks:
- Cognitive Impairment: The transient “fog” reported could reflect reduced synaptic plasticity or altered neurotransmitter release, raising concerns for long‑term use.
- Motivational Deficits: Diminished motivation may impact adherence to lifestyle interventions critical for obesity management.
- Emotional Blunting: Reduced amygdala reactivity could blunt affective responsiveness, potentially affecting quality of life.
2.5 Regulatory and Post‑Marketing Surveillance
The U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA) currently classify GLP‑1 drugs as Class B therapeutics for obesity, with post‑marketing commitments for long‑term safety. The new neurological data will likely trigger additional risk‑management plans (RMPs), requiring systematic collection of neurocognitive outcomes in Phase IV studies. Companies may also be required to update labeling to reflect potential CNS effects.
3. Integrating Corporate Governance and Scientific Innovation
Novo Nordisk’s dual challenges—tax transparency and emerging CNS safety signals—highlight the intersection of corporate stewardship and scientific responsibility.
- Governance: Addressing tax transparency will require the adoption of robust disclosure frameworks, potentially aligning with the OECD’s Base‑Erosion and Profit‑Shifting (BEPS) action plans.
- Research: Continued investment in neuroimaging and cognitive phenotyping is essential to delineate the therapeutic window of GLP‑1 agonists. Multidisciplinary collaborations with neurologists, psychiatrists, and neuroscientists will be pivotal for refining clinical trial designs.
Investor perception will hinge on the company’s ability to navigate these complex terrains. A proactive stance—such as publishing a clear tax policy and launching a dedicated neurocognitive safety study—could mitigate reputational risk and reinforce Novo Nordisk’s position as a leader in both therapeutic innovation and corporate responsibility.
